Gene · 2829
NIH grants1,173
NIH grants whose papers are about the gene, through NIH's grant-paper links.
421 to 440 of 1,173
Download this page as JSON| Grant | Title | XCR1 papers | Newest fiscal year |
|---|---|---|---|
| P01AI056299 | T Cell Costimulatory Pathways: Functions and Interactions | 1 | 2023 |
| P01CA165980 | Molecular Tumorigenesis of Bladder Cancer | 1 | 2023 |
| P01HL107202 | Exploring the biology of persistent type 2 airway niches in asthma | 1 | 2023 |
| P50CA221703 | The University of Texas MD Anderson Cancer Center SPORE in Melanoma | 1 | 2023 |
| P50HD060848 | Novel therapeutics for FSHD | 1 | 2023 |
| R01AG028082 | Mechanisms of dysregulated immunity with aging | 1 | 2023 |
| R01AI039614 | Tracking CD4+ Memory T Cells in Vivo | 1 | 2023 |
| R01AI106352 | Transcriptional Control of Natural Killer Cell Development | 1 | 2023 |
| R01AI136756 | Next Generation Broadly Neutralizing Antibodies to Clear HIV-1 Reservoir | 1 | 2023 |
| R01AI141333 | Micro-Particle Delivery of a Potent Intracellular Adjuvant for a Universal Flu Vaccine | 1 | 2023 |
| R01AI141436 | Impairment of B cell Responses by Pathogenic Chikungunya Viruses | 1 | 2023 |
| R01AI143861 | Novel lung resident interstitial macrophage subset with distinct localization and polarization | 1 | 2023 |
| R01AI145997 | Transcriptional mechanisms of natural killer cell responses during mouse cytomegalovirus infection | 1 | 2023 |
| R01AR063611 | Genetic and Genomic Dissection of Psoriatic Arthritis | 1 | 2023 |
| R01AR077926 | B cell depletion to prevent autoimmunity | 1 | 2023 |
| R01CA163649 | Targeting MUC1-Mediated Tumor-Stromal Metabolic Cross-Talk in Pancreatic Cancer | 1 | 2023 |
| R01CA222695 | Identification and cloning of neoantigen-specific T cells for GBM immunotherapy | 1 | 2023 |
| R01CA230275 | Understanding and Overcoming Resistance to Cancer Immunotherapy Due to Defective Antigen Presentation | 1 | 2023 |
| R01CA233512 | Functional reprogramming of tumor-MDSC through antibody-based therapies targeting Notch ligands | 1 | 2023 |
| R01CA233794 | Reverse-engineering precision liver cancer chemoprevention | 1 | 2023 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2829/grants?page=22